Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 713

1.
2.

Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.

Weiner M, Benator D, Burman W, Peloquin CA, Khan A, Vernon A, Jones B, Silva-Trigo C, Zhao Z, Hodge T; Tuberculosis Trials Consortium.

Clin Infect Dis. 2005 May 15;40(10):1481-91. Epub 2005 Apr 14.

3.
4.

Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use.

Nettles RE, Mazo D, Alwood K, Gachuhi R, Maltas G, Wendel K, Cronin W, Hooper N, Bishai W, Sterling TR.

Clin Infect Dis. 2004 Mar 1;38(5):731-6. Epub 2004 Feb 17.

5.

Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis.

Khan FA, Minion J, Pai M, Royce S, Burman W, Harries AD, Menzies D.

Clin Infect Dis. 2010 May 1;50(9):1288-99. doi: 10.1086/651686. Review.

6.

Adherence to treatment of latent tuberculosis infection in a clinical population in New York City.

Li J, Munsiff SS, Tarantino T, Dorsinville M.

Int J Infect Dis. 2010 Apr;14(4):e292-7. doi: 10.1016/j.ijid.2009.05.007. Epub 2009 Aug 4.

7.

Twice-weekly, directly observed treatment for HIV-infected and uninfected tuberculosis patients: cohort study in rural South Africa.

Davies GR, Connolly C, Sturm AW, McAdam KP, Wilkinson D.

AIDS. 1999 May 7;13(7):811-7.

PMID:
10357380
8.
9.

Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis.

Burman W, Benator D, Vernon A, Khan A, Jones B, Silva C, Lahart C, Weis S, King B, Mangura B, Weiner M, El-Sadr W; Tuberculosis Trials Consortium.

Am J Respir Crit Care Med. 2006 Feb 1;173(3):350-6. Epub 2005 Aug 18.

PMID:
16109981
11.

Risk factors for relapse in human immunodeficiency virus type 1 infected adults with pulmonary tuberculosis.

Johnson JL, Okwera A, Vjecha MJ, Byekwaso F, Nakibali J, Nyole S, Milberg J, Aisu T, Whalen CC, Mugerwa RD, Ellner JJ.

Int J Tuberc Lung Dis. 1997 Oct;1(5):446-53.

PMID:
9441100
12.

Relapse in persons treated for drug-susceptible tuberculosis in a population with high coinfection with human immunodeficiency virus in New York City.

Driver CR, Munsiff SS, Li J, Kundamal N, Osahan SS.

Clin Infect Dis. 2001 Nov 15;33(10):1762-9. Epub 2001 Oct 10.

13.

[Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].

Saito W, Nagayama N, Miyamoto M, Hara H, Suzuki J, Masuda K, Baba M, Tamura A, Nagai H, Akagawa S, Kawabe Y, Machida K, Kurashima A, Yotsumoto H.

Kekkaku. 2003 Oct;78(10):611-7. Japanese.

PMID:
14621568
15.

Use of rifabutin in the treatment of pulmonary tuberculosis.

Grassi C, Peona V.

Clin Infect Dis. 1996 Apr;22 Suppl 1:S50-4. Review.

16.

Treatment outcomes of patients with HIV and tuberculosis.

Nahid P, Gonzalez LC, Rudoy I, de Jong BC, Unger A, Kawamura LM, Osmond DH, Hopewell PC, Daley CL.

Am J Respir Crit Care Med. 2007 Jun 1;175(11):1199-206. Epub 2007 Feb 8.

17.

Tuberculosis and drug resistance among patients seen at an AIDS Reference Center in São Paulo, Brazil.

Pinto WP, Hadad DJ, Silva Telles MA, Ueki SY, Palaci M, Basile MA.

Int J Infect Dis. 2001;5(2):93-100.

PMID:
11468105
18.

An epidemiological study of tuberculosis and HIV infection in Tanzania, 1991-1993.

Chum HJ, O'Brien RJ, Chonde TM, Graf P, Rieder HL.

AIDS. 1996 Mar;10(3):299-309.

PMID:
8882670
19.

Rifampin-monoresistant tuberculosis in New York City, 1993-1994.

Munsiff SS, Joseph S, Ebrahimzadeh A, Frieden TR.

Clin Infect Dis. 1997 Dec;25(6):1465-7.

20.
Items per page

Supplemental Content

Write to the Help Desk